Ectopic Otoconin 90 expression in triple negative breast cancer cell lines is associated with metastasis functions

Alexander Pearlman, Mohammed Tanjimur Rahman, Kinnari Upadhyay, Johnny C. Loke, Harry Ostrer

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Triple negative breast cancer (TNBC) is an aggressive tumor with propensity to metastasize and poor treatment options. Improving treatment options would be impactful; thus, finding a tumor-specific cell surface protein with metastasis promoting functions that could be knocked out was the goal of this study. The Otoconin 90 gene (OC90), frequently amplified in tumors on chromosome 8q24.22, was identified as a potential therapeutic candidate. Normally OC90 is expressed in the cochlea with no known function in other normal tissues. In silico analysis of The Cancer Genome Atlas (TCGA) multi-tumor RNAseq cohorts revealed that OC90 is expressed in many tumor types at high prevalence and genomic amplification is associated with the elevated mRNA expression. In vitro assays in TNBC cell lines revealed OC90 expression with control over cell viability, apoptosis and invasion. RNA-seq analysis of OC90-siRNA knockdown and OC90-overexpression in BT20, BT549, HCC38 cell lines identified co-expressed transcripts, HMGA2, POLE2 and TRIB3. Altered expression of HMGA2, POLE2 and TRIB3 was predictive of survival among members of the Metabric breast cancer cohort. Thus, OC90 represents a potential therapeutic target whose knockdown could improve the treatment of TNBC.

Original languageEnglish (US)
Article numbere0211737
JournalPLoS ONE
Volume14
Issue number2
DOIs
StatePublished - Feb 1 2019

Fingerprint

Triple Negative Breast Neoplasms
metastasis
breast neoplasms
Genes
Cells
cell lines
Neoplasm Metastasis
Cell Line
Tumors
neoplasms
Neoplasms
genes
Gene Knockdown Techniques
therapeutics
gene overexpression
Atlases
Cochlea
surface proteins
small interfering RNA
Computer Simulation

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Ectopic Otoconin 90 expression in triple negative breast cancer cell lines is associated with metastasis functions. / Pearlman, Alexander; Rahman, Mohammed Tanjimur; Upadhyay, Kinnari; Loke, Johnny C.; Ostrer, Harry.

In: PLoS ONE, Vol. 14, No. 2, e0211737, 01.02.2019.

Research output: Contribution to journalArticle

@article{bd814332de064078b836d205a0d74815,
title = "Ectopic Otoconin 90 expression in triple negative breast cancer cell lines is associated with metastasis functions",
abstract = "Triple negative breast cancer (TNBC) is an aggressive tumor with propensity to metastasize and poor treatment options. Improving treatment options would be impactful; thus, finding a tumor-specific cell surface protein with metastasis promoting functions that could be knocked out was the goal of this study. The Otoconin 90 gene (OC90), frequently amplified in tumors on chromosome 8q24.22, was identified as a potential therapeutic candidate. Normally OC90 is expressed in the cochlea with no known function in other normal tissues. In silico analysis of The Cancer Genome Atlas (TCGA) multi-tumor RNAseq cohorts revealed that OC90 is expressed in many tumor types at high prevalence and genomic amplification is associated with the elevated mRNA expression. In vitro assays in TNBC cell lines revealed OC90 expression with control over cell viability, apoptosis and invasion. RNA-seq analysis of OC90-siRNA knockdown and OC90-overexpression in BT20, BT549, HCC38 cell lines identified co-expressed transcripts, HMGA2, POLE2 and TRIB3. Altered expression of HMGA2, POLE2 and TRIB3 was predictive of survival among members of the Metabric breast cancer cohort. Thus, OC90 represents a potential therapeutic target whose knockdown could improve the treatment of TNBC.",
author = "Alexander Pearlman and Rahman, {Mohammed Tanjimur} and Kinnari Upadhyay and Loke, {Johnny C.} and Harry Ostrer",
year = "2019",
month = "2",
day = "1",
doi = "10.1371/journal.pone.0211737",
language = "English (US)",
volume = "14",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "2",

}

TY - JOUR

T1 - Ectopic Otoconin 90 expression in triple negative breast cancer cell lines is associated with metastasis functions

AU - Pearlman, Alexander

AU - Rahman, Mohammed Tanjimur

AU - Upadhyay, Kinnari

AU - Loke, Johnny C.

AU - Ostrer, Harry

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Triple negative breast cancer (TNBC) is an aggressive tumor with propensity to metastasize and poor treatment options. Improving treatment options would be impactful; thus, finding a tumor-specific cell surface protein with metastasis promoting functions that could be knocked out was the goal of this study. The Otoconin 90 gene (OC90), frequently amplified in tumors on chromosome 8q24.22, was identified as a potential therapeutic candidate. Normally OC90 is expressed in the cochlea with no known function in other normal tissues. In silico analysis of The Cancer Genome Atlas (TCGA) multi-tumor RNAseq cohorts revealed that OC90 is expressed in many tumor types at high prevalence and genomic amplification is associated with the elevated mRNA expression. In vitro assays in TNBC cell lines revealed OC90 expression with control over cell viability, apoptosis and invasion. RNA-seq analysis of OC90-siRNA knockdown and OC90-overexpression in BT20, BT549, HCC38 cell lines identified co-expressed transcripts, HMGA2, POLE2 and TRIB3. Altered expression of HMGA2, POLE2 and TRIB3 was predictive of survival among members of the Metabric breast cancer cohort. Thus, OC90 represents a potential therapeutic target whose knockdown could improve the treatment of TNBC.

AB - Triple negative breast cancer (TNBC) is an aggressive tumor with propensity to metastasize and poor treatment options. Improving treatment options would be impactful; thus, finding a tumor-specific cell surface protein with metastasis promoting functions that could be knocked out was the goal of this study. The Otoconin 90 gene (OC90), frequently amplified in tumors on chromosome 8q24.22, was identified as a potential therapeutic candidate. Normally OC90 is expressed in the cochlea with no known function in other normal tissues. In silico analysis of The Cancer Genome Atlas (TCGA) multi-tumor RNAseq cohorts revealed that OC90 is expressed in many tumor types at high prevalence and genomic amplification is associated with the elevated mRNA expression. In vitro assays in TNBC cell lines revealed OC90 expression with control over cell viability, apoptosis and invasion. RNA-seq analysis of OC90-siRNA knockdown and OC90-overexpression in BT20, BT549, HCC38 cell lines identified co-expressed transcripts, HMGA2, POLE2 and TRIB3. Altered expression of HMGA2, POLE2 and TRIB3 was predictive of survival among members of the Metabric breast cancer cohort. Thus, OC90 represents a potential therapeutic target whose knockdown could improve the treatment of TNBC.

UR - http://www.scopus.com/inward/record.url?scp=85061491166&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061491166&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0211737

DO - 10.1371/journal.pone.0211737

M3 - Article

C2 - 30763339

AN - SCOPUS:85061491166

VL - 14

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 2

M1 - e0211737

ER -